Riga, Latvia

Edit A Pule

This inventor holds 1 USPTO granted patent. Top assignee: Other. Active years: 1986.


% Patents Active = 100.0

Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:

goldMedal1 out of 834,453 
Other
 patents

Years Active: 1986

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Edit A Pule - Innovator in Pharmaceutical Preparations

Introduction

Edit A Pule is a notable inventor based in Riga, Latvia. She has made significant contributions to the field of pharmaceuticals, particularly in the treatment of hypertensive diseases. Her innovative approach has led to the development of a unique pharmaceutical preparation that addresses critical health issues.

Latest Patents

Edit A Pule holds a patent for a novel pharmaceutical preparation aimed at treating hypertensive disease and myocardial infarction. This preparation includes as an active ingredient (1,1-dimethyl-3-oxopyrazolidin-1-io-4-yl)acetate, combined with a pharmaceutically acceptable vehicle. This innovative formulation represents a significant advancement in the treatment options available for patients suffering from these conditions.

Career Highlights

Throughout her career, Edit A Pule has demonstrated a commitment to advancing medical science through her research and inventions. Her work has not only contributed to the pharmaceutical industry but has also provided new hope for patients dealing with serious health challenges.

Collaborations

Edit A Pule has collaborated with esteemed colleagues such as Valdis D Mikazhan and Anatoly S Birman. These partnerships have enhanced her research efforts and contributed to the successful development of her patented pharmaceutical preparation.

Conclusion

Edit A Pule is a pioneering inventor whose work in pharmaceutical preparations has the potential to improve the lives of many individuals suffering from hypertensive diseases. Her innovative spirit and dedication to research continue to inspire advancements in the medical field.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…